6 results
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
March 31, | December 31, | |||||||
2024 | 2023 | |||||||
($'000) | ($'000) | |||||||
Accrued research and development costs | $ | 566 | $ | 1,821 | ||||
Accrued legal fees | 375 | 266 | ||||||
Accrued bonus | 428 | 1,624 | ||||||
Accrued audit fees | 417 | 671 | ||||||
Accrued professional fees | 353 | 338 | ||||||
Accrued local taxes | — | 382 | ||||||
Other accrued expenses | 400 | 365 | ||||||
Total | $ | 2,539 | $ | 5,467 |
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
The following table sets forth the compensation awarded to, earned by or paid to each of our named executive officers for the years indicated.
Name and Principal Position | Year | Salary | Bonus (3) | Stock Awards (4) | Option Awards (4) | All Other Compensation (5) | Total (3) | |||||||||||||||||||||
($) | ($) | ($) | ($) | ($) | ($) | |||||||||||||||||||||||
Dr. Denise Scots-Knight (1) (2) | 2023 | 565,107 | 254,298 | 285,358 | 1,043,403 | 71,157 | 2,219,323 | |||||||||||||||||||||
Chief Executive Officer | 2022 | 506,809 | 304,085 | — | 1,358,134 | 68,219 | 2,237,247 | |||||||||||||||||||||
Charles Sermon (2) | 2023 | 415,651 | 162,104 | 99,540 | 362,923 | 48,031 | 1,088,249 | |||||||||||||||||||||
General Counsel | 2022 | 372,772 | 186,386 | — | 339,533 | 51,198 | 949,889 | |||||||||||||||||||||
Christine Fox (2) | 2023 | 378,120 | 151,248 | 91,043 | 340,240 | 40,400 | 1,001,051 | |||||||||||||||||||||
Chief Financial Officer | 2022 | 332,833 | 166,416 | — | 271,627 | 40,063 | 810,939 |
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
Company performance was assessed against the 2023 Company-wide target objectives, including certain pipeline and development milestones, execution of manufacturing, clinical and compliance processes and partnerships, the achievement of finance-related and business development milestones. As a result, the named executive officers were awarded bonuses against their target bonus rates as follows.
Name | 2023 Target Bonus Rate (% of base salary) | 2023 Stretch Bonus Rate (% of base salary) | 2023 Bonus Achievement (% of base salary) | |||||||||
Dr. Denise Scots-Knight | 60 | % | 75 | % | 45 | % | ||||||
Charles Sermon | 50 | % | 63 | % | 39 | % | ||||||
Christine Fox | 50 | % | 63 | % | 40 | % |
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
Name | 2023 Target Bonus Rate (% of base salary) | 2023 Stretch Bonus Rate (% of base salary) | 2023 Bonus Achievement (% of base salary) | ||
Dr. Denise Scots-Knight | 60% | 75% | 45% | ||
Charles Sermon | 50% | 63% | 39% | ||
Christine Fox | 50% | 63% | 40% |
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
December 31, | ||||||||
2023 | 2022 | |||||||
($'000) | ($'000) | |||||||
Accrued research and development costs | $ | 1,821 | $ | 2,336 | ||||
Accrued legal fees | 266 | 132 | ||||||
Accrued bonus | 1,624 | 1,863 | ||||||
Accrued audit fees | 671 | 382 | ||||||
Accrued professional fees | 338 | 183 | ||||||
Accrued local taxes | 382 | — | ||||||
Other accrued expenses | 365 | 540 | ||||||
Total | $ | 5,467 | $ | 5,436 |
10-K
b5sk19x dclg
27 Mar 24
Annual report
5:20pm
- Prev
- 1
- Next